<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Bexarotene</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00307</strong>&#160; (APRD00114)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Bexarotene (Targretin) is an antineoplastic agent indicated by the <span class="caps">FDA</span> for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi&#8217;s sarcoma. [Wikipedia]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00307/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00307/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00307.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00307.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00307.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00307.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00307.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00307">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>4-[1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl]benzoic acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IUPAC</td></tr><tr><td>4-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl)ethenyl]benzoic acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>USAN</td></tr><tr><td>Bexaroten</td><td>German</td><td>INN</td></tr><tr><td>Bexarot&#232;ne</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>DCF</td></tr><tr><td>Bexarotene</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>BAN, USAN</td></tr><tr><td>Bexarotenum</td><td>Latin</td><td>INN</td></tr><tr><td>p-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl]benzoic acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>WHO</td></tr><tr><td>Targretyn</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>Ligand</td></tr><tr><td>Targrexin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>Ligand</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Targretin</td><td>Eisai</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>153559-49-0</td></tr><tr><th>Weight</th><td>Average: 348.4779<br>Monoisotopic: 348.20893014</td></tr><tr><th>Chemical Formula</th><td>C<sub>24</sub>H<sub>28</sub>O<sub>2</sub></td></tr><tr><th>InChI Key</th><td>NAVMQTYZDKMPEU-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C24H28O2/c1-15-13-20-21(24(5,6)12-11-23(20,3)4)14-19(15)16(2)17-7-9-18(10-8-17)22(25)26/h7-10,13-14H,2,11-12H2,1,3-6H3,(H,25,26)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC1=CC2=C(C=C1C(=C)C1=CC=C(C=C1)C(O)=O)C(C)(C)CCC2(C)C</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Lipids</td></tr><tr><th>Class</th><td>Prenol Lipids</td></tr><tr><th>Subclass</th><td>Retinoids</td></tr><tr><th>Direct parent</th><td>Retinoids</td></tr><tr><th>Alternative parents</th><td>Aromatic Monoterpenes; Tetralins; Phenylpropenes; Benzoic Acids; Benzoyl Derivatives; Styrenes; Toluenes; Carboxylic Acids; Enolates; Polyamines</td></tr><tr><th>Substituents</th><td>tetralin; p-cymene; phenylpropene; benzoic acid; benzoic acid or derivative; styrene; benzoyl; toluene; benzene; carboxylic acid derivative; carboxylic acid; polyamine; enolate</td></tr><tr><th>Classification description</th><td>This compound belongs to the retinoids. These are compounds that are related to vitamin A, especially retinol.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Used orally for the treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy. Also used topically for the treatment of skin lesions in early (stage IA and IB) CTCL in patients who experience refractory or persistent disease with the use of other therapies or are intolerant of other therapies.</td></tr><tr><th>Pharmacodynamics</th><td>Bexarotene is a member of a subclass of retinoids that selectively activate retinoid X receptors (RXRs). These retinoid receptors have biologic activity distinct from that of retinoic acid receptors (RARs). Bexarotene is indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. Bexarotene selectively binds and activates retinoid X receptor subtypes (RXR<sub>&#945;</sub>, RXR<sub>&#946;</sub>, RXR<sub>&#947;</sub>). RXRs can form heterodimers with various receptor partners such as retinoic acid receptors (RARs), vitamin D receptor, thyroid receptor, and peroxisome proliferator activator receptors (PPARs). Once activated, these receptors function as transcription factors that regulate the expression of genes that control cellular differentiation and proliferation. Bexarotene inhibits the growth <i>in vitro</i> of some tumor cell lines of hematopoietic and squamous cell origin. It also induces tumor regression <i>in vivo</i> in some animal models.</td></tr><tr><th>Mechanism of action</th><td>Bexarotene selectively binds with and activates retinoid X receptor subtypes. There are three subtypes in total: RXR<sub>&#945;</sub>, RXR<sub>&#946;</sub>, RXR<sub>&#947;</sub>. The exact mechanism of action of bexarotene in the treatment of CTCL is unknown but the drug has activity in all clinical stages of CTCL.</td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>&gt;99%</td></tr><tr><th>Metabolism</th><td class="data-table-container"></td></tr><tr><th>Route of elimination</th><td>Urinary elimination of bexarotene and its known metabolites is a minor excretory pathway (</td></tr><tr><th>Half life</th><td>7 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9954</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9022</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.794</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6283</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5369</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7182</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8496</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7722</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6786</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8171</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8724</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.5589</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.8351</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8138</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.6458</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8592
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7898
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.933
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.2119 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9703
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9034
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Eisai inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.catalent.com">Catalent Pharma Solutions</a></li>
<li><a href="http://www.contractpharma.com">Contract Pharm</a></li>
<li><a href="http://www.eisai.com">Eisai Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td></td></tr><tr><td>Gel</td><td>Topical</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00872">Conivaptan</a></td><td>Conivaptan may increase the serum concentration of CYP3A4 substrates such as bexarotene. Upon completion/discontinuation of conivaptan, allow at least 7 days before initiating therapy with drugs that are CYP3A4 substrates. Consider therapy modification.</td></tr><tr><td><a href="/drugs/DB00618">Demeclocycline</a></td><td>Tetracycline derivatives like demeclocycline may enhance the adverse/toxic effect of Retinoic Acid Derivatives. Due to the risk of developing pseudotumor cerebri (also known as intracranial hypertension), avoid this combination of drugs if possible. If used concomitantly, monitor for evidence of this interaction (eg, dizziness, diplopia, headache).</td></tr><tr><td><a href="/drugs/DB00304">Desogestrel</a></td><td>Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of desogestrel, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form).</td></tr><tr><td><a href="/drugs/DB00254">Doxycycline</a></td><td>Tetracycline derivatives like doxycycline may enhance the adverse/toxic effect of Retinoic Acid Derivatives. Due to the risk of developing pseudotumor cerebri (also known as intracranial hypertension), avoid this combination of drugs if possible. If used concomitantly, monitor for evidence of this interaction (eg, dizziness, diplopia, headache).  </td></tr><tr><td><a href="/drugs/DB01395">Drospirenone</a></td><td>Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of drospirenone, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form).</td></tr><tr><td><a href="/drugs/DB00823">Ethynodiol</a></td><td>Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of ethynodiol diacetate it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form).</td></tr><tr><td><a href="/drugs/DB00294">Etonogestrel</a></td><td>Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of etonogestrel, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form).</td></tr><tr><td><a href="/drugs/DB01241">Gemfibrozil</a></td><td>Gemfibrozil may increase the serum concentration of bexarotene. This combination should be avoided.</td></tr><tr><td><a href="/drugs/DB00367">Levonorgestrel</a></td><td>Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of levonorgestrel, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form).</td></tr><tr><td><a href="/drugs/DB00603">Medroxyprogesterone Acetate</a></td><td>Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of medroxyprogesterone, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form).</td></tr><tr><td><a href="/drugs/DB01017">Minocycline</a></td><td>Tetracycline derivatives like minocycline may enhance the adverse/toxic effect of Retinoic Acid Derivatives. Due to the risk of developing pseudotumor cerebri (also known as intracranial hypertension), avoid this combination of drugs if possible. If used concomitantly, monitor for evidence of this interaction (eg, dizziness, diplopia, headache).  </td></tr><tr><td><a href="/drugs/DB06713">Norelgestromin</a></td><td>Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of norelgestromin, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form).</td></tr><tr><td><a href="/drugs/DB00717">Norethindrone</a></td><td>Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of norethindrone, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form).</td></tr><tr><td><a href="/drugs/DB00957">Norgestimate</a></td><td>Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of norgestimate, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form).</td></tr><tr><td><a href="/drugs/DB00759">Tetracycline</a></td><td>Tetracycline may enhance the adverse/toxic effect of Retinoic Acid Derivatives. Due to the risk of developing pseudotumor cerebri (also known as intracranial hypertension), avoid this combination of drugs if possible. If used concomitantly, monitor for evidence of this interaction (eg, dizziness, diplopia, headache).  </td></tr><tr><td><a href="/drugs/DB00560">Tigecycline</a></td><td>Tigecycline may enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri (intracranial hypertension) is of particular concern. Avoid this combination.</td></tr><tr><td><a href="/drugs/DB00162">Vitamin A</a></td><td>Bexarotene increases the risk of vitamin A toxicity. Avoid vitamin A supplementation while taking bexarotene.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>